VRTX — Vertex Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $101.91bn
- $91.11bn
- $9.87bn
- 92
- 24
- 74
- 68
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 3,808 | 6,659 | 7,525 | 10,779 | 11,218 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 634 | 885 | 1,137 | 1,442 | 1,563 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 4,823 | 8,133 | 9,561 | 13,235 | 14,144 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 833 | 1,284 | 1,424 | 1,456 | 1,453 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 8,318 | 11,752 | 13,433 | 18,151 | 22,730 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1,335 | 1,878 | 2,142 | 2,742 | 3,547 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 2,233 | 3,065 | 3,333 | 4,238 | 5,150 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 6,085 | 8,687 | 10,100 | 13,913 | 17,580 |
Total Liabilities & Shareholders' Equity | 8,318 | 11,752 | 13,433 | 18,151 | 22,730 |
Total Common Shares Outstanding |